Effects on abstinence of nicotine patch treatment before quitting smoking: Parallel, two arm, pragmatic randomised trial: The preloading investigators

The BMJ

Volumn 361, Issue , 2018, Pages

  Aveyard, Paul ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE PATCH; VARENICLINE;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ELECTRONIC HEALTH RECORD; ENGLAND; FEMALE; HOSPITAL ADMISSION; HUMAN; MALE; NATIONAL HEALTH SERVICE; NICOTINE REPLACEMENT THERAPY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE;

EID: 85137959515     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.k2164     Document Type: Article

References (37)

1. West R, Brown J. Theory of Addiction. Addiction Press, 2014.
2. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004;99:29-38. doi:10.1111/j.1360-0443.2004.00540.x
3. West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl) 2008;197:371-7. doi:10.1007/ s00213-007-1041-3
4. Gries JM, Benowitz N, Verotta D. Importance of chronopharmacokinetics in design and evaluation of transdermal drug delivery systems. J Pharmacol Exp Ther 1998;285:457-63.
5. Lindson N, Aveyard P. An updated meta-analysis of nicotine preloading for smoking cessation: investigating mediators of the effect. Psychopharmacology (Berl) 2011;214:579-92. doi:10.1007/ s00213-010-2069-3
6. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012;11:CD000146. doi:10.1002/14651858.CD000146.pub4
7. Fagerström KO, Hughes JR. Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: a review. Nicotine Tob Res 2002;4(Suppl 2):S73-9.
8. Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji AR. Use of varenicline for weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. Arch Intern Med 2011;171:770-7. doi:10.1001/archinternmed.2011.138.
9. Hawk LWJr, Ashare RL, Lohnes SF, et al. The effects of extended pre-quit varenicline treatment on smoking behavior and shortterm abstinence: a randomized clinical trial. Clin Pharmacol Ther 2012;91:172-80. doi:10.1038/clpt.2011.317
10. Hawk LWJr, Ashare RL, Rhodes JD, Oliver JA, Cummings KM, Mahoney MC. Does Extended Pre Quit Bupropion Aid in Extinguishing Smoking Behavior? Nicotine Tob Res 2015;17:1377-84. doi:10.1093/ntr/ ntu347
11. Lindson-Hawley N, Coleman T, Docherty G, et al. Nicotine patch preloading for smoking cessation (the preloading trial): study protocol for a randomized controlled trial. Trials 2014;15:296. doi:10.1186/1745-6215-15-296
12. Rose JE. Nicotine preloading: the importance of a precessation reduction in smoking behavior. Psychopharmacology (Berl) 2011;217:453-4. doi:10.1007/s00213-011-2350-0
13. Flaxman J. Quitting smoking now or later: Gradual, abrupt, immediate, and delayed quitting. Behav Ther 1978;9:260-70. doi:10.1016/S0005-7894(78)80111-7
14. National Institute for Health and Clinical Excellence. Guidance on smoking cessation. Report 2008.
15. Hajek P. Withdrawal-oriented therapy for smokers. Br J Addict 1989;84:591-8. doi:10.1111/j.1360-0443.1989. tb03474.x
16. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86:1119-27. doi:10.1111/j.1360-0443.1991.tb01879.x
17. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005;100:299-303. doi:10.1111/j.1360-0443.2004.00995.x
18. Shiffman S, West R, Gilbert D, SRNT Work Group on the Assessment of Craving and Withdrawal in Clinical Trials. Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob Res 2004;6:599-614. doi:10.1080/146222004 10001734067
19. Lindson-Hawley N, Banting M, West R, Michie S, Shinkins B, Aveyard P. Gradual Versus Abrupt Smoking Cessation: A Randomized, Controlled Noninferiority Trial. Ann Intern Med 2016;164:585-92. doi:10.7326/M14-2805
20. Marteau TM, Aveyard P, Munafò MR, et al. Effect on adherence to nicotine replacement therapy of informing smokers their dose is determined by their genotype: a randomised controlled trial. PLoS One 2012;7:e35249. doi:10.1371/journal.pone.0035249
21. Aveyard P, Johnson C, Fillingham S, Parsons A, Murphy M. Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial. BMJ 2008;336:1223-7. doi:10.1136/ bmj.39545.852616.BE
22. Fidler J, Ferguson SG, Brown J, Stapleton J, West R. How does rate of smoking cessation vary by age, gender and social grade? Findings from a population survey in England. Addiction 2013;108:1680-5. doi:10.1111/add.12241
23. West R, Ussher M. Is the ten-item Questionnaire of Smoking Urges (QSU-brief) more sensitive to abstinence than shorter craving measures? Psychopharmacology (Berl) 2010;208:427-32. doi:10.1007/s00213-009-1742-x
24. Aveyard P, Brown K, Saunders C, et al. Weekly versus basic smoking cessation support in primary care: a randomised controlled trial. Thorax 2007;62:898-903. doi:10.1136/thx.2006.071837
25. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013;(5):CD009329. doi:10.1002/14651858.CD009329.pub2
26. OECD. Education at a glance 2014. OECD, 2014: 1-11.
27. Parsons A, Ingram J, Inglis J, et al. A proof of concept randomised placebo controlled factorial trial to examine the efficacy of St John's wort for smoking cessation and chromium to prevent weight gain on smoking cessation. Drug Alcohol Depend 2009;102:116-22. doi:10.1016/j.drugalcdep.2009.02.006
28. Begh R, Munafò MR, Shiffman S, et al. Lack of attentional retraining effects in cigarette smokers attempting cessation: a proof of concept double-blind randomised controlled trial. Drug Alcohol Depend 2015;149:158-65. doi:10.1016/j.drugalcdep.2015.01.041
29. Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 2009;49:57-71. doi:10.1146/annurev.pharmtox.48.113006.094742
30. Committee on Safety of Medicines. Report of the Committee on Safety of Medicines Working Group on nicotine replacement therapy. MHRA, 2005:1-20.
31. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996;335:1792-8. doi:10.1056/ NEJM199612123352402.
32. Hubbard R, Lewis S, Smith C, et al. Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tob Control 2005;14:416-21. doi:10.1136/tc.2005.011387
33. Zevin S, Jacob P3rd, Benowitz NL. Dose-related cardiovascular and endocrine effects of transdermal nicotine. Clin Pharmacol Ther 1998;64:87-95. doi:10.1016/S0009-9236(98)90026-1
34. Rose JE, Behm FM. Adapting smoking cessation treatment according to initial response to precessation nicotine patch. Am J Psychiatry 2013;170:860-7. doi:10.1176/appi. ajp.2013.12070919
35. National Institute for Health and Clinical Excellence. Stop smoking services. National Institute for Health and Clinical Excellence, 2008.
36. Bauld L, Hiscock R, Dobbie F, et al. English Stop-Smoking Services: One-Year Outcomes. Int J Environ Res Public Health 2016;13:1175. doi:10.3390/ijerph13121175
37. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016;387:2507-20. doi:10.1016/S0140-6736(16)30272-0